{"id":876110,"date":"2025-08-14T18:35:06","date_gmt":"2025-08-14T22:35:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-announces-second-quarter-2025-financial-results-and-highlights-recent-activity\/"},"modified":"2025-08-14T18:35:06","modified_gmt":"2025-08-14T22:35:06","slug":"inhibikase-therapeutics-announces-second-quarter-2025-financial-results-and-highlights-recent-activity","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibikase-therapeutics-announces-second-quarter-2025-financial-results-and-highlights-recent-activity\/","title":{"rendered":"Inhibikase Therapeutics Announces Second Quarter\u00a02025 Financial Results and Highlights Recent Activity"},"content":{"rendered":"
\n

BOSTON and ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (\u201cInhibikase\u201d or \u201cCompany\u201d), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension (\u201cPAH\u201d), today reported financial results for the quarter ended June 30, 2025 and highlighted recent developments.<\/p>\n

\u201cDuring our second quarter of 2025, we continued to position the Company to advance IKT-001 toward a late-stage clinical trial in PAH,\u201d said Mark Iwicki, Chief Executive Officer of Inhibikase. \u201cWe have now finalized our study protocol, and we expect to initiate our Phase 2b clinical study of IKT-001, our re-engineered prodrug of imatinib mesylate, in PAH in the second half of 2025.\u201d<\/p>\n

Multiple studies including both Phase 2 and the Phase 3 IMPRES study previously demonstrated that imatinib mesylate (\u201cimatinib\u201d), an anti-proliferative tyrosine kinase inhibitor, was highly efficacious in PAH. Notably in the IMPRES study, patients that maintained 400 mg of imatinib for greater than 50% of the treatment period showed a placebo adjusted 45-meter improvement in 6-minute walk distance (\u201c6MWD\u201d) which represents best-in-class improvements for patients afflicted by PAH. More recently, a contemporary study in the American Journal of Respiratory and Critical Care Medicine<\/em> demonstrated that higher exposures of imatinib were associated with a larger improvement in total pulmonary resistance (\u201cTPR\u201d). The 400 mg dose of imatinib exhibited the greatest impact on TPR and, even though the majority of patients completed the study at 200 mg or less, the magnitude of the hemodynamic change for the study was noted to compare favorably with recent studies of novel therapies added to background treatment. The Company believes this supports its thesis that IKT-001 has the potential to minimize GI side effects while maximizing the highly efficacious outcomes observed at 400 mg across multiple studies.<\/p>\n

\n Recent Developments:<\/strong>\n <\/p>\n